About Gossamer Bio
Gossamer Bio is a company based in San Diego (United States) founded in 2017 by Faheem Hasnain. Gossamer Bio has raised $330 million across 4 funding rounds from investors including Arch Venture Partners, Monashee Investment Management and EcoR1. The company has 145 employees. Gossamer Bio has completed 1 acquisition, including Respira Therapeutics. Gossamer Bio offers products and services including Seralutinib. Gossamer Bio operates in a competitive market with competitors including Aclaris Therapeutics, Escient Pharmaceuticals, Nimbus Therapeutics, Alpine Immune Sciences and Septerna, among others.
- Headquarter San Diego, United States
- Employees 145
- Founders Faheem Hasnain
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Phoneβ’β’β’β’ β’β’β’β’
- Website gossamerbio.com
- Social LinkedIn X
- Legal Name Gossamer Bio, Inc.
- Annual Revenue$48.47 M (USD)-57.74as on Dec 31, 2025
- Net Profit-$170.37 M (USD)-201.39as on Dec 31, 2025
- EBITDA-$162.25 M (USD)-190.94as on Dec 31, 2025
- Total Equity Funding$330M (USD)
in 4 rounds
- Latest Funding Round$212.1M (USD), Post-IPO
Jul 2023
- InvestorsArch Venture Partners
& 11 more
- Employee Count145
- Investments & Acquisitions
Products & Services of Gossamer Bio
Gossamer Bio offers a comprehensive portfolio of products and services, including Seralutinib.
Inhaled inhibitor for treating pulmonary hypertension diseases.
Funding Insights of Gossamer Bio
Gossamer Bio has successfully raised a total of $330M across 4 strategic funding rounds. The most recent funding activity was a Post-IPO round of $212.1 million completed in July 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $330M
- Total Rounds 4
- Last Round Post-IPO β $212.1M
- First Round $100M
(Jan 2018)
- Investors Count 12
All 4 funding rounds of Gossamer Bio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2023 | $212.1M | Post-IPO | β | β | β |
| Jul 2022 | $120.04M | Post-IPO | β | β | |
| Jul 2018 | $230M | Series B | β | Hillhouse | |
| Jan 2018 | $100M | Series A | β | Arch Venture Partners, Omega Funds | β |
12 investors in total: 12 institutional.
Investors in Gossamer Bio
Gossamer Bio has secured backing from 12 investors, including institutional and venture fund investors. Prominent investors backing the company include Arch Venture Partners, Monashee Investment Management and EcoR1.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital investments are offered to startups by NEA. | – | nea.com | Menlo Park, United States | |
Early-stage and late-stage biotech and finance companies are funded. | – | rockspringscapital.com | Baltimore, United States | |
Long-term private equity investments in transformational opportunities are pursued. | – | invus.com | New York, United States | |
Global private equity investments are managed with long-term focus. | – | hillhouseinvestment.com | New York, United States | |
Venture capital firm focused on life science companies | 1986 | archventure.com | Chicago, United States | |
US focused venture capital firm | – | polarispartners.com | Boston, United States | |
Venture capital firm | – | omegafunds.com | Boston, United States | |
- | – | ecor1cap.com | - | |
Asset management firm emphasizing rationality, integrity, and problem-solving approaches. | 2002 | weissasset.com | Boston, United States | |
Investment management firm providing advisory and career services to clients. | 2020 | madisonavenuepartners.com | New York, United States |
Investor details for Gossamer Bio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Gossamer Bio
85 people are tracked at Gossamer Bio (51 in leadership, 3 in board & advisors, 31 in team); the tracked headcount is 145.
| Name | Role | Group |
|---|---|---|
Faheem Hasnain | Co-Founder, CEO & Chairman | Leadership |
Lisa Nolan | MD & President, Gossamer Bio Ireland | Leadership |
Lee Ann McDowell | Senior Director, Medical Affairs | Leadership |
John Kempen | Sr. Vice President | Leadership |
Michael Laffan | Senior Director Of Finance And Operations | Leadership |
Ananth Bheemavarapu | Senior Director, Statistical Programming | Leadership |
Daniel O'Connell | Associate Director | Leadership |
Binal Patel | Director, Clinical Quality Assurance | Leadership |
Sidra Hoffman | Senior Director, Clinical Development- Pulmonary Vascular Disease | Leadership |
Danielle Wiener | Associate Director, Clinical Supply Chain | Leadership |
Iris Gil | Director, Translational Medicine Operations | Leadership |
Richard Aranda | Chief Medical Officer | Leadership |
Bryan Giraudo | COO & CFO | Leadership |
Robin Osterhout | Executive Director | Leadership |
Bhushan Kanumuri | Director, Statistical Programming | Leadership |
Jennifer Weidman | Vice President Regulatory Affairs | Leadership |
Daniel Bachteler Ph.D., Msc | Director, Publications & Scientific Communications | Leadership |
Jeanette Sprague | Associate Director, Translational Medicine Operations | Leadership |
Conor O'Donovan | Senior Vice President, Regulatory Affairs | Leadership |
Kartik Raghupathi | Vice President Biostatistics | Leadership |
65 more people are available in the full profile.
Complete people profiles for Gossamer Bio
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Gossamer Bio
Gossamer Bio is a publicly listed company on the NASDAQ with ticker symbol GOSS in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date08 Feb 2019
- Listed onNASDAQ: GOSS
- Listed entityGossamer Bio, Inc.
- Exchange sectorHealth technology
- ISINUS38341P2011
- Share price$9.31 (-5.77% on the day) · 2026-10-09
- Market capitalisation$56.9M
- EPS (diluted, trailing year)$-55.67
- Volume (last session)290,997
Financials of Gossamer Bio
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $48.5M | -$170.4M | -$162.2M |
| 2024 | $114.7M | -$56.5M | -$55.8M |
| 2023 | – | -$179.8M | -$169.4M |
| 2022 | – | -$229.4M | -$214.1M |
| 2021 | – | -$234.0M | -$208.5M |
Detailed financial statements for Gossamer Bio
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Gossamer Bio
Gossamer Bio has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Respira Therapeutics.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Therapeutics to treat Pulmonary Arterial Hypertension using proprietary drug delivery technology. | respiratherapeutics.com | Albuquerque, United States | 2010 | Sep 2025 | β’β’β’β’ |
Complete acquisition details for Gossamer Bio
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Gossamer Bio
5 dated milestones of Gossamer Bio across 8 years, from founding to its latest funding, stage changes and deals.
- Founded Gossamer Bio is founded.
- Funding First funding round of $100.0M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $212.1M.
- Acquisition Acquires Respira Therapeutics.
Competitors of Gossamer Bio
Gossamer Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Aclaris Therapeutics, Escient Pharmaceuticals, Nimbus Therapeutics, Alpine Immune Sciences and Septerna, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| aclaristx.com | 2012 | Malvern, United States | $82M | 180 | Novel dermatologic therapies are developed for skin conditions. | |
| escientpharma.com | 2017 | San Diego, United States | $237.5M | 44 | Small molecule therapeutics for inflammatory diseases are developed. | |
| nimbustx.com | 2009 | Cambridge, United States | $685M | 81 | Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed. | |
| alpineimmunesciences.com | 2015 | Seattle, United States | $49.25M | 126 | Developer of immunotherapies to treat cancer and autoimmune disorders | |
| septerna.com | 2020 | San Bruno, United States | $250M | – | GPCR drug discovery platform is developed for multiple diseases. | |
| upstreambio.com | 2021 | Waltham, United States | $400M | – | Therapeutics for allergic and inflammatory diseases are developed. | |
| acelyrin.com | 2020 | Los Angeles, United States | $550M | – | Immunological drug candidates are developed for severe diseases. | |
| calcimedica.com | 2006 | San Diego, United States | $76.66M | 11 | CRAC channel inhibitors are developed for inflammatory diseases. |
Detailed competitors of Gossamer Bio
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Gossamer Bio
The website of Gossamer Bio (gossamerbio.com) receives about 12.4K visits a month and ranks #1,804,330 among all websites worldwide, #2,452 in Biotechnology and Pharmaceuticals.
- Monthly visits12.4K
▼ 5.2% vs previous month
- Unique visitors7K
per month
- Global rank#1,804,330
among all websites
- Category rank#2,452
Health · Biotechnology and Pharmaceuticals
- Bounce rate48%
- Pages per visit1.8
- Average visit34 sec
- DevicesDesktop 58% Β· Mobile 42%
Latest news on Gossamer Bio
Complete news archive for Gossamer Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Gossamer Bio
10 companies that operate in the same segment as Gossamer Bio (Immunology & Cancer Therapeutics), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | – | – | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Targeted therapies for cancer treatment are developed. | 2005 | Waltham, Massachusetts, United States | USD 198.29 M | USD 172.35 M | 270 | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 215.5 M | USD 29.62 M | 225 | |
Plasma-based biologics are developed for immune deficiency and infectious diseases. | 2005 | Ramsey, Minnesota, United States | USD 17.55 M | USD 510.17 M | 685 | |
Antibody drugs for cancer treatment are developed. | 2015 | Singapore, Singapore | USD 150 M | – | – | |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | 2003 | United States | USD 171.85 M | USD 102.48 M | 338 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Gossamer Bio
Gossamer Bio was founded in 2017 and raised its 1st funding round 1 year after it was founded.
Gossamer Bio is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Faheem Hasnain is the current CEO of Gossamer Bio. They have also founded this company.
Gossamer Bio is a funded company, having raised a total of $330M across 4 funding rounds to date. The company's 1st funding round was a Series A of $100M, raised on Jan 2018.
Gossamer Bio has 145 employees.
Annual revenue of Gossamer Bio is $48.47M as on Dec 31, 2025.
Gossamer Bio was founded in 2017 and is headquartered in San Diego, United States. Operations focus on the biotechnology sector, where small molecule-based therapies are developed to address immunological disorders, inflammation, and cancer. Drug candidates include GB001, targeted at inflammatory disorders with an undisclosed mechanism, and first-in-class HIF-1Ξ± stabilizers designed for inflammatory bowel diseases.
Gossamer Bio's top competitors include Escient Pharmaceuticals, Nimbus Therapeutics and Alpine Immune Sciences.
Gossamer Bio offers Seralutinib.
Yes, Gossamer Bio is publicly traded on NASDAQ under the ticker symbol GOSS.
Gossamer Bio has made 1 acquisition, including Respira Therapeutics.
Gossamer Bio has 12 investors. Key investors include Arch Venture Partners, Monashee Investment Management, EcoR1, NEA, and Weiss Asset Management.